Discuss the rationale for Pfizers bid,and explain why Kraft-Cadbury Essay

controvert the rationale for Pfizers bid,and explain why Kraft-Cadbury has influenced the governments stance on mergers and acquisitions - Essay ExampleSuch kind of revolt looks scary whereby the fund practicers from both Axa and Jupiter will be so disap time perioded according to the steps taken by AstraZenecas board although cannot cause an alarm to an extend resulting to resignation. Mr Lelf Johansson who is the AstraZeneca chairman said that all fissiparous directors in most cases are paid to give their opinion, in case the shareholders seem not to bid such opinion the most likely repercussion is for them to appoint new specify of directors.While at Axa together with co sulk, it is clear that Mr. Johansson and his staff should be appreciated because of the wise decision they took on behalf of their smart set and being calm despite of the difficult times very few company Bosses can guide the way he did to succeed. It has now become clear if not impossible that AstraZeneca s board could manage to think of any option apart from the 55 bid if it has to maintain its credibility-at least before the set up date expires for the takeover panel. And since now Pfizer has the ability to bid even higher than 55 under the prevailing panels rules, the whole drama seems to be over now (Depamphilis, 2005).There is no correct explanation as to the reason leading to 60-ish would stand to be the right tag price. Its all obvious that all manner of bid battles of which at the end the winner takes it all. The starting point for Pfizer was poor and not impressive, few considered its opening target of 50 a long shot at the moment but the ecstasy rapidly dropped to 48 leading to the share drop down of close 6% meaning that the value of its cash together with the share proposal were affected.Under the terms it was supposed(a) to be that the offer for each AstraZeneca shareholder to walk away with 1.845 shares as a group firearm 15.98 placed in cash. According to the Pfiz er closing share stood at the price worthy $31.15, this means that the offer comes to about GBP50 per each available AstraZeneca